UAE – Emirates Health Services (EHS) has entered into an initial arrangement with Johnson & Johnson’s Middle East branch to enhance the health services sector and foster collaboration across medical disciplines.
The collaboration with the US company will set a framework for a more comprehensive data-driven partnership aimed to support hospitals and healthcare professionals
The agreement specified three main areas of collaboration – educational program and training courses, strategic solutions program, and public awareness program.
The collaboration with Johnson & Johnson will set a framework for a more comprehensive data-driven partnership that aims to support hospitals and healthcare professionals, achieve better outcomes, improve patient experience, and reduce the total cost of care.
The agreement calls for collaboration to implement public awareness programs and campaigns covering various diseases, such as obesity, cancer, and atrial fibrillation.
The agreement, signed by Dr. Yousif Mohammed Al-Serkal, Director-General of EHS, and Loai Abu Elhawa, general manager – MedTech Gulf at Johnson & Johnson, also calls for collaboration to implement public awareness programs and campaigns covering various diseases such as obesity, cancer, and atrial fibrillation.
The agreement specified three main areas of collaboration – educational program and training courses, strategic solutions program, and public awareness program.
Furthermore, the two parties are set to work together to launch the ‘Silent Noise Campaign’ to raise awareness about and destigmatize mental health conditions – focusing particularly on schizophrenia and depression.
This campaign is in line with EHS’ strategy to drive positive change and combat stereotypes associated with mental health.
Meanwhile, Dr. Al Zarooni explained that signing the agreement aligns with EHS’ aspirations to advance the health services sector and foster collaboration across all medical specialties, paving the way for new accomplishments that cement the UAE healthcare sector’s leadership.
Earlier on, Emirates Health Services entered into a memorandum of understanding (MoU) with Novo Nordisk Pharma Gulf to collaborate on areas of common interest, most notably in healthcare innovation.
The MoU, signed by Dr. Yousif Mohammed Al Serkal, Director-General of EHS, and Mads Bo Larsen, vice president and general manager of Novo Nordisk Pharma Gulf, envisages the pharma company providing 12 months of free treatment with its oral Semaglutide drug for 50 patients with type 2 diabetes.
The agreement will also support physicians in the emirate with scientific communication for management of the disease.
The two entities will also collaborate on educational programs and panel discussions for healthcare providers at hospitals and healthcare centres under the EHS umbrella that offer diabetes treatments.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
